---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-114487"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:34:26.678315+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Recursion amends Exscientia acquisition to clarify post-closing board appointments

## Summary
- Amendment lets Exscientia designate one board member (subject to Recursion board approval) effective at closing; a second member if mutually agreed.
- Supplemental disclosures reveal deal discussions began Oct 2022 with an exploratory 'merger of equals' proposal between CEOs.
- Disclosed Exscientia risk-adjusted revenue forecast: $18M (2024E) rising to $659M (2049E); Recursion revenue forecast $30M (2024E) to $627M (2049E).
- Centerview DCF implied Exscientia equity value $3.90–$6.60 per share; analyst price targets gave implied exchange ratio range of 0.4118x–1.1250x (actual 0.7729x).
- Recursion formed a Transaction Committee in July 2024 to oversee negotiations; no additional compensation or conflicts noted.

## SEC filing metadata
- accession: 0001104659-24-114487
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000110465924114487/0001104659-24-114487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000110465924114487/tm2427472d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-114487
- JSON: https://secwatch.observer/filing/0001104659-24-114487.json
- Plain text: https://secwatch.observer/filing/0001104659-24-114487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.